Found: 8
Select item for more details and to access through your institution.
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
- Published in:
- Pituitary, 2015, v. 18, n. 3, p. 385, doi. 10.1007/s11102-014-0585-6
- By:
- Publication type:
- Article
Erratum to: Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.
- Published in:
- 2015
- By:
- Publication type:
- Erratum
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
- Published in:
- Pituitary, 2014, v. 17, n. 2, p. 132, doi. 10.1007/s11102-013-0478-0
- By:
- Publication type:
- Article
Erratum to: Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
- Published in:
- 2014
- By:
- Publication type:
- Erratum
Pharmacokinetics, Pharmacodynamics, and Safety of Pasireotide LAR in Patients With Acromegaly: A Randomized, Multicenter, Open-Label, Phase I Study.
- Published in:
- Journal of Clinical Pharmacology, 2014, v. 54, n. 11, p. 1308, doi. 10.1002/jcph.326
- By:
- Publication type:
- Article
Pasireotide (SOM230), a Novel Multireceptor-Targeted Somatostatin Analogue, Is Well Tolerated When Administered as a Continuous 7-Day Subcutaneous Infusion in Healthy Male Volunteers.
- Published in:
- Journal of Clinical Pharmacology, 2012, v. 52, n. 7, p. 1017, doi. 10.1177/0091270011408727
- By:
- Publication type:
- Article
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
- Published in:
- BMC Endocrine Disorders, 2016, v. 16, p. 1, doi. 10.1186/s12902-016-0096-8
- By:
- Publication type:
- Article
Phase 1 dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors.
- Published in:
- OncoTargets & Therapy, 2017, v. 10, p. 3177, doi. 10.2147/OTT.S128547
- By:
- Publication type:
- Article